Strategic partnerships Recent exposure to Big Pharma and tiered biomanufacturing players (Teva, Evotec) suggests Just Biotherapeutics has visibility and interest from large potential clients or partners. Leverage these signals to position for contract manufacturing collaborations, tech licensing, or joint development opportunities.

Biologics focus Company specializes in biotherapeutics from molecule to manufacturing, indicating a strong value proposition for firms needing end-to-end design-to-scale solutions. Target biotech startups and mid-sized biologics programs seeking integrated design and manufacturing acceleration.

Emerging revenue Reported revenue under one million dollars alongside multiple fundraising rounds historically indicates growth potential and a need for scalable manufacturing partnerships. Approach with pilot programs, feasibility studies, or staged services to minimize client risk.

Tech-enabled A broad technology stack including AWS, Azure, MATLAB, SAS, and Smartsheet signals a modern, data-driven approach. Propose sales motions around digital tooling, data analytics acceleration, and cloud-enabled process development collaborations.

Funding trajectory Past funding rounds (Series A2 and Series B) imply investor interest and validating momentum. Use this to engage strategic investors or co-development deals, and align proposals with funding milestones, grant opportunities, or milestone-based payments.